Lycia Therapeutics director holds 33,269 shares

Q: What LYCA stock options did Laurent Fischer report?

He reported two direct options, each covering 13,307 common shares. One has a $2.44 exercise price and expires June 27, 2034; the other has a $3.70 exercise price and expires August 10, 2036. Each award vests in 1/48 installments, subject to service on each vesting date.

The options have different exercise prices and expiration dates, and their monthly vesting is subject to service on each vesting date.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Lycia Therapeutics, Inc. director Laurent Fischer reported direct ownership of 33,269 common shares as of October 22, 2026, plus two direct stock-option positions, each covering 13,307 common shares. One option has a $2.44 exercise price and expires June 27, 2034; the other has a $3.70 exercise price and expires August 10, 2036. Each award vests in 1/48 installments, subject to service on each vesting date; the initial vesting dates were July 27, 2024, and September 6, 2026, respectively.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Fischer Laurent

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy) ^F1	--	--	--
holding	Stock Option (Right to Buy) ^F2	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 26,614 contracts (Direct); Common Stock — 33,269 shares (Direct)

Footnotes (2)

F1. The options vested as to 1/48 of the total award on July 27, 2024, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2. The options vested as to 1/48 of the total award on September 6, 2026, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

Direct common shares: 33,269 shares Option underlying shares: 13,307 common shares Option underlying shares: 13,307 common shares +4 more

7 metrics

Direct common shares 33,269 shares Reported as of October 22, 2026

Option underlying shares 13,307 common shares Stock option with a $2.44 exercise price; expiration June 27, 2034

Option underlying shares 13,307 common shares Stock option with a $3.70 exercise price; expiration August 10, 2036

Exercise price $2.44 per share Stock option expiring June 27, 2034

Exercise price $3.70 per share Stock option expiring August 10, 2036

Option expiration June 27, 2034 Option with a $2.44 exercise price

Option expiration August 10, 2036 Option with a $3.70 exercise price

Key Terms

Stock Option (Right to Buy), vest monthly, provision of service

3 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

vest monthly financial

"an additional 1/48 of the award will vest monthly thereafter"

provision of service financial

"subject to the Reporting Person's provision of service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LYCA shares does Laurent Fischer report?

Laurent Fischer, a director of Lycia Therapeutics, reported direct ownership of 33,269 common shares as of October 22, 2026.

What LYCA stock options did Laurent Fischer report?

He reported two direct options, each covering 13,307 common shares. One has a $2.44 exercise price and expires June 27, 2034; the other has a $3.70 exercise price and expires August 10, 2036. Each award vests in 1/48 installments, subject to service on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/24/2026 - 08:14 PM EDT Accepted by SEC EDGAR 10/22/2026 - 07:19 PM EDT

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Fischer Laurent

(Last)

(First)

(Middle)

C/O LYCIA THERAPEUTICS, INC.

400 EAST JAMIE COURT, SUITE 200

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
10/22/2026

3. Issuer Name and Ticker or Trading Symbol
Lycia Therapeutics, Inc. [ LYCA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	33,269	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽¹⁾	06/27/2034	Common Stock	13,307	$2.44	D
Stock Option (Right to Buy)	⁽²⁾	08/10/2036	Common Stock	13,307	$3.7	D

Explanation of Responses:

1. The options vested as to 1/48 of the total award on July 27, 2024, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

2. The options vested as to 1/48 of the total award on September 6, 2026, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Amy Bachrodt, Attorney-in-Fact	10/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR